Table 2.
Biochemical and clinical variables measured at baseline and after 3 months in subjects according to therapy.
| Empagliflozin group |
Incretin group |
|||
|---|---|---|---|---|
| Baseline | 3 months | Baseline | 3 months | |
| Number | 20 | 20 | 15 | 15 |
| Body weight (kg) | 89 ± 14 | 85 ± 13* | 80 ± 8 | 79 ± 10 |
| BMI (kg/m2) | 30 ± 4 | 29 ± 4* | 27 ± 3 | 26 ± 3 |
| Waist (cm) | 107 ± 10 | 105 ± 10* | 102 ± 7 | 100 ± 8 |
| SBP (mmHg) | 141 ± 14 | 136 ± 16 | 136 ± 23 | 135 ± 12 |
| DBP (mmHg) | 86 ± 11 | 84 ± 10 | 78 ± 8 | 79 ± 9 |
| HR (bpm) | 75 ± 11# | 69 ± 17 | 62 ± 6 | 69 ± 9 |
| FPG (mmol/L) | 10.3 ± 3.1 | 7.9 ± 1.1* | 9.7 ± 1.7 | 8.1 ± 0.9* |
| HbA1c (%) | 8.4 ± 0.7 | 7.6 ± 0.9* | 8.3 ± 0.7 | 7.7 ± 0.9^ |
| Total-chol (mmol/L) | 4.09 ± 0.91 | 4.12 ± 0.98 | 4.51 ± 1.40 | 4.17 ± 1.17* |
| HDL-chol (mmol/L) | 1.11 ± 0.34 | 1.19 ± 0.31* | 0.98 ± 0.31 | 1.04 ± 0.28 |
| LDL-chol (mmol/L) | 2.20 ± 0.78 | 2.28 ± 0.91 | 2.31 ± 1.17 | 2.25 ± 0.88 |
| Triglycerides (mmol/L) | 1.76 ± 1.18 | 1.45 ± 0.67 | 2.13 ± 1.55 | 1.88 ± 1.29 |
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; FPG: fasting plasma glucose; HbA1c: glycated haemoglobin; HDL: high-density lipoprotein; LDL: low-density lipoprotein; SD: standard deviation.
The data are expressed as the means ± SDs; t-test for paired data *p < 0.002, ^p < 0.02 versus baseline; t-test for unpaired data #p = 0.01 versus the incretin group.